Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2023 1
2024 1
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.
Beltrame L, Mannarino L, Sergi A, Velle A, Treilleux I, Pignata S, Paracchini L, Harter P, Scambia G, Perrone F, González-Martin A, Berger R, Arenare L, Hietanen S, Califano D, Derio S, Van Gorp T, Dalessandro ML, Fujiwara K, Provansal M, Lorusso D, Buderath P, Masseroli M, Ray-Coquard I, Pujade-Lauraine E, Romualdi C, D'Incalci M, Marchini S. Beltrame L, et al. Among authors: derio s. ESMO Open. 2025 Jun;10(6):105060. doi: 10.1016/j.esmoop.2025.105060. Epub 2025 May 19. ESMO Open. 2025. PMID: 40393377 Free PMC article.
CONCLUSIONS: The study demonstrates that HR-SC is a novel, clinically feasible solution with a low failure rate for predicting HRR status in OC patients and underscores the importance of leveraging ML approaches for advancing precision oncology in the era of personalized m …
CONCLUSIONS: The study demonstrates that HR-SC is a novel, clinically feasible solution with a low failure rate for predicting HRR status in …
Myeloid neoplasms post PARP inhibitors for ovarian cancer.
Caruso G, Gigli F, Parma G, Lapresa M, Derio S, Palaia I, Colombo N. Caruso G, et al. Among authors: derio s. Int J Gynecol Cancer. 2023 Apr 3;33(4):598-606. doi: 10.1136/ijgc-2022-004190. Int J Gynecol Cancer. 2023. PMID: 36707087 Free article. Review.
The incidence of myeloid neoplasms following treatment with poly (ADP-ribose) polymerase inhibitors (PARPi) in patients with ovarian cancer has been gradually increasing over the last few years. ...Fortunately, the earlier introduction of PARPi in the frontline setting red …
The incidence of myeloid neoplasms following treatment with poly (ADP-ribose) polymerase inhibitors (PARPi) in patients with ovarian …
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms.
Valenza C, Mongillo M, Gigli F, Trapani D, Katrini J, Nicolò E, Boldrini L, Boscolo Bielo L, Castellano G, Guidi L, Pellizzari G, Derio S, Lapresa M, Parma G, Derenzini E, Curigliano G, Colombo N. Valenza C, et al. Among authors: derio s. ESMO Open. 2024 Sep;9(9):103685. doi: 10.1016/j.esmoop.2024.103685. Epub 2024 Aug 29. ESMO Open. 2024. PMID: 39214046 Free PMC article.
BACKGROUND: Among patients with advanced high-grade ovarian carcinoma (aHGOC) treated with poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis), the presence of a germline BRCA pathogenic variant (gBRCA-PV) may increase the risk of bone marrow mutagenesis resulting in postcyto …
BACKGROUND: Among patients with advanced high-grade ovarian carcinoma (aHGOC) treated with poly (ADP-ribose) polymerase (PARP) inhibitors (P …
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study.
Valenza C, Nicolò E, Mongillo M, Trapani D, Katrini J, Boldrini L, Boscolo Bielo L, Castellano G, Guidi L, Pellizzari G, Villa J, Derio S, Lapresa M, Gigli F, Parma G, Omodeo Salè E, Derenzini E, Curigliano G, Colombo N. Valenza C, et al. Among authors: derio s. Oncologist. 2025 Jul 4;30(7):oyae330. doi: 10.1093/oncolo/oyae330. Oncologist. 2025. PMID: 39607864 Free PMC article.
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
Valenza C, Mongillo M, Visconti MV, Katrini J, Trapani D, Boldrini L, Guidi L, Farfalla A, Malengo D, Caruso G, Derio S, Lapresa M, Parma G, Biagioli E, Omodeo Salé E, Curigliano G, Colombo N. Valenza C, et al. Among authors: derio s. Gynecol Oncol. 2025 Mar;194:11-17. doi: 10.1016/j.ygyno.2025.01.014. Epub 2025 Feb 8. Gynecol Oncol. 2025. PMID: 39923679
METHODS: We conducted a single-center, retrospective, cohort study to evaluate the activity of platinum rechallenge in patients with high-grade ovarian cancer, progressing on at least one non-platinum regimen for platinum-resistant disease, from January 2010 to June 2024, at the …
METHODS: We conducted a single-center, retrospective, cohort study to evaluate the activity of platinum rechallenge in patients with high-gr …
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49).
Colombo N, Parma G, Tasca G, Di Palma MP, Tognon G, Lissoni AA, Fossati R, Carlucci L, Zucchetti M, Matteo C, Ferrero A, Bologna A, Mantiero M, Wimberger P, Katsaros D, Tomao F, Galli F, Lapresa M, Guarneri V, Ficarelli S, Canova S, Derio S, Girardi F, Zizioli V, Katrini J, Massa D, Rulli E, Biagioli E; NEWTON study group. Colombo N, et al. Among authors: derio s. Eur J Cancer. 2026 Mar 27;239:116685. doi: 10.1016/j.ejca.2026.116685. Online ahead of print. Eur J Cancer. 2026. PMID: 41950571